Kura Oncology Reports Q2 FY25 Financial Results, $630.7mln Cash on Hand

• Kura Oncology reports Q2 2025 financial results • FDA reviews NDA for ziftomenib in R/R NPM1-m AML • Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 • Commercial readiness activities underway • KOMET-017-IC and NIC phase 3 studies to start in 2H 2025 • Three clinical abstracts accepted for 2025 ESMO Congress • $630.7 million in pro forma cash for ziftomenib commercialization

Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its second quarter 2025 financial results. The company will release the results after the close of U.S. financial markets on Thursday, August 7, 2025, and will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update [1].

The financial results announcement will provide investors with an update on Kura Oncology's financial performance, including revenue, earnings, and cash flow. The company's management will discuss the company's progress in its clinical trials and the development of its pipeline of cancer treatment therapies. Investors are encouraged to tune in to the webcast and conference call to gain insights into Kura Oncology's financial performance and strategic plans [2].

Kura Oncology's pipeline includes small molecule drug candidates designed to target cancer signaling pathways. The company's lead product candidate, ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), has received significant regulatory attention. In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin to develop and commercialize ziftomenib for AML and other hematologic malignancies [1].

The FDA has granted Priority Review for ziftomenib in relapsed/refractory NPM1-mutant AML, with a Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025. The company reported $15.3 million in collaboration revenue and ended Q2 with $630.7 million in cash. Key clinical achievements include positive results from the KOMET-001 pivotal trial showing a 23% complete remission rate and promising data from KOMET-007 Phase 1b expansion cohort [3].

Kura Oncology is preparing for the commercial launch of ziftomenib, with plans to initiate two Phase 3 trials in frontline AML settings in the second half of 2025. The company also plans to present three clinical abstracts from its FTI program at the 2025 ESMO Congress. The company's strong financial position, with $630.7 million in cash as of June 30, 2025, provides a solid foundation for these activities [3].

References:
[1] https://www.marketbeat.com/earnings/reports/2025-8-14-kura-oncology-inc-stock/
[2] https://www.stocktitan.net/news/KURA/kura-oncology-to-report-second-quarter-2025-financial-pq95gy1oznjv.html
[3] https://www.stocktitan.net/news/KURA/kura-oncology-reports-second-quarter-2025-financial-mmr9u8q8zsnk.html